Leqvio (Inclisiran)

Inclisiran is a small interfering RNA that targets the messenger RNA for proprotein convertase subtilisin/kexin type 9 (PCSK9) in liver cells. By silencing PCSK9 production, it increases the number of LDL receptors on hepatocytes, enhancing removal of LDL‑cholesterol from the bloodstream.

The dose of Leqvio is determined by the prescribing clinician. It is administered as a subcutaneous injection, and the prescribing information specifies the interval and amount based on the individual patient's clinical needs.

Safety of Leqvio during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Leqvio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Leqvio belongs to the siRNA class that reduces PCSK9 synthesis, offering a dosing schedule that may be less frequent than monoclonal antibody PCSK9 inhibitors. Both classes lower LDL‑cholesterol, but inclisiran’s mechanism is intracellular gene silencing, whereas antibodies bind circulating PCSK9 protein.

Leqvio should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Leqvio is given as a subcutaneous injection into the abdomen, thigh, or upper arm. The injection is performed by a qualified healthcare professional according to the dosing schedule prescribed by the treating physician.

Serious adverse events include severe allergic reactions such as anaphylaxis or angioedema, significant elevations in liver enzymes, and rare cases of muscle injury that could indicate rhabdomyolysis. Patients should seek immediate medical attention if they experience symptoms of these conditions.

Leqvio is contraindicated in individuals with known hypersensitivity to inclisiran or any component of the formulation. Caution is also advised for patients with uncontrolled liver disease, and it should not be used in pregnancy or lactation unless the benefits outweigh the risks.